📣A CEPI-funded first-ever Phase II Lassa vaccine trial has been launched by IAVI in Nigeria.

The trial at @HJFMRI in Abuja is designed in consultation with partners including NCDC and the Nigeria Lassa Vaccine Taskforce.

cepi.net/participants-n…

More than 600 participants are expected to enrol in the trial, which is also due to take place in Liberia and Ghana, pending regulatory approval.

Lassa fever is a viral disease typically spread by multimammate rats, causing acute haemorrhagic disease in many countries across West Africa.

Current annual rates of infection are thought to be vastly underestimated and research has warned cases could grow significantly because